BMY
$59.71
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
Recent News
READYSTATE Dumps 361,000 Workiva Shares Worth $32 Million
This technology firm provides cloud-based compliance and reporting solutions for organizations with complex regulatory needs worldwide.
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Will Anktiva Continue to Drive ImmunityBio's Top-Line Growth in 2026?
IBRX's Anktiva fueled a 700% revenue surge in 2025, but can repeat prescriptions, global expansion and BCG shortages sustain momentum into 2026?
How New Oral Immunology Wins At Bristol Myers Squibb (BMY) Have Changed Its Investment Story
Earlier this month, Bristol Myers Squibb reported positive interim Phase 3 SUCCESSOR-2 results for oral mezigdomide in relapsed or refractory multiple myeloma and secured U.S. FDA approval for Sotyktu as the first TYK2 inhibitor to treat adults with active psoriatic arthritis. Together, these updates highlight Bristol Myers Squibb’s push to extend its immunology and oncology franchises with differentiated, orally administered therapies in serious chronic diseases. We’ll now examine how...
Bristol Myers Squibb (BMY) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Bristol Myers Squibb (BMY) settling at $59.71, representing a +1.07% change from its previous close.